Literature DB >> 2340513

Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.

R W Brueggemeier1, N E Katlic.   

Abstract

7 alpha-(4'-Amino)phenylthio-1,4-androstadiene-3,17-dione (7 alpha-APTADD), a potent enzyme-activated irreversible inhibitor, was examined in two different human cell culture lines, MCF-7 human mammary carcinoma cells and JAr choriocarcinoma cells. Both the MCF-7 and JAr cell culture systems exhibit aromatase activity, and 7 alpha-APTADD was evaluated for its aromatase-inhibitory activity, for its ability to inactivate the enzyme complex, and for the time course of recovery of enzymatic activity. This inhibitor produced a dose-dependent inhibition of aromatase activity in MCF-7 cells and in JAr cells, with EC50 values of 91 and 7.3 nM, respectively. Two other steroidal inhibitors, 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione and 4-hydroxyandrostenedione, produced similar dose-response curves and EC50 values, while the nonsteroidal aminoglutethimide was less effective. Both cell culture systems exhibited prolonged inhibition of aromatase activity following exposure to 7 alpha-APTADD, suggesting enzyme inactivation by this inhibitor. Thus, 7 alpha-APTADD is an effective inhibitor of aromatase in MCF-7 mammary carcinoma cells and in JAr choriocarcinoma cells. These studies encourage further development of this group of medicinal agents for the treatment of estrogen-dependent mammary carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

2.  Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.

Authors:  Yu Zheng; Bo Yu; Wanlop Weecharangsan; Longzhu Piao; Michael Darby; Yicheng Mao; Rumiana Koynova; Xiaojuan Yang; Hong Li; Songlin Xu; L James Lee; Yasuro Sugimoto; Robert W Brueggemeier; Robert J Lee
Journal:  Int J Pharm       Date:  2010-02-13       Impact factor: 5.875

Review 3.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

4.  Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.

Authors:  H P Ciolino; T T Wang; N Sathyamoorthy
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.